Accessibility Menu
Boiron logo

Boiron(OTC) BOIRF

Market Cap$546.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+37%
5 Year+5%
1 Year+22%
1 Month+4%
$31.50
+0.00%
+0.00Today
Boiron last closing stock price
MetricPriceDate
Last closeUSD 31.502026-07-06
Boiron stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.86%USD 30.332026-06-17
1 month+3.86%USD 30.332026-05-19
3 month+10.43%USD 28.522026-03-24
Year to date+10.43%USD 28.522025-11-13
1 year+22.12%USD 25.792025-05-23
3 year+4.74%USD 30.072023-06-13
5 year+4.76%USD 30.072021-05-20
Since inception+36.66%USD 23.052004-01-07

Boiron Financials at a Glance

Market Cap

$546.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€988.57M

Net Income (TTM)

€43.97M

EPS (TTM)

$2.14

P/E Ratio

14.69

Dividend

$1.57

Beta (Volatility)

-0.01 (Low)

Price

$31.50

Volume

200

Open

$31.50

Previous Close

$31.50

Daily Range

$31.50 - $31.50

52-Week Range

$24.30 - $32.28

Estimated Earnings Date

Sep 18, 2025

BOIRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Boiron

Boiron S.A. is a prominent pharmaceutical company specializing in the global development and sale of homeopathic treatments. Established in 1932, the company has a strong market presence in France, Europe, North America, and various international markets.

Products and Services
  • Homeopathic products for various health concerns, including Oscillococcinum and Arnigel
  • Dietary supplements and herbal medicines, such as Canephron
  • Medical devices, including COVID-19 self-tests and rapid antigenic tests
Growth Outlook
  • Revenue of €255.36 million in Q4 2025, showing consistent demand
  • Net income of €21.27 million in Q4 2025, indicating strong profitability
  • Dividend yield of 5.04% TTM, reflecting commitment to shareholder returns
Financial Highlights
  • Trailing twelve months (TTM) revenue of €1.01 billion, demonstrating robust sales performance
  • Operating income margin of 7.82% in Q4 2025, showcasing operational efficiency
  • Current ratio of 2.22 TTM, indicating strong liquidity position
AI Generated • Jul 27, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2,634

CEO

Pascal Houdayer, MBA

Website

www.boironfinance.com

Headquarters

Messimy, 69510, FR

BOIRF Financials

Key Financial Metrics (TTM)

Gross Margin

72.98%

Operating Margin

7.06%

Net Income Margin

6.51%

Return on Equity

8.57%

Return on Capital

8.34%

Return on Assets

5.41%

Earnings Yield

6.81%

Dividend Yield

4.98%

Payout Ratio

63.83%

Stock Overview

Market Cap

$546.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.36M

Volume

200

Avg. Volume

8.413

Financials (TTM)

Gross Profit

€724.42M

Operating Income

€51.13M

EBITDA

€124.25M

Operating Cash Flow

€95.17M

Capital Expenditure

-€31.41M

Free Cash Flow

€63.76M

Cash & ST Invst.

€79.31M

Total Debt

€31.47M

Boiron Performance Analysis

Boiron annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 561,471,4684.4%
20232023-12-31EUR 533,258,109-5.0%
20242024-12-31EUR 527,388,063-1.1%
20252025-12-31EUR 565,537,1837.2%
Boiron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-9.9%
Q42024-12-3113.5%
Q22025-06-30-5.2%
Q42025-12-314.0%
Boiron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 2.7040.1%
20232023-12-31EUR 2.23-17.4%
20242024-12-31EUR 0.71-68.3%
20252025-12-31EUR 2.12200.5%
Boiron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-83.8%
Q42024-12-31142.1%
Q22025-06-3041.3%
Q42025-12-3189.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

€255.36M

+0.8%

Gross Profit

€184.60M

+0.8%

Gross Margin

72.29%

N/A

Market Cap

$546.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$207.64K

N/A

Employees

2,634

N/A

Net Income

€21.27M

+4.5%

EBITDA

€35.64M

+4.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€79.31M

+7.1%

Total Debt

€31.47M

+129.7%

Accounts Receivable

€109.45M

+25.9%

Inventory

€98.56M

+1.9%

Long Term Debt

€18.73M

+181.9%

Short Term Debt

€12.74M

+80.5%

Return on Assets

5.41%

N/A

Return on Invested Capital

7.52%

N/A

Free Cash Flow

€15.55M

-33.7%

Operating Cash Flow

€27.51M

-5.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VRNOFVerano Holdings Corp.
$1.30+8.33%
AGYTFAllergy Therapeutics plc
$0.15+0.00%
CLVSFCellaVision AB (publ)
$14.00+0.00%
ELTPElite Pharmaceuticals, Inc.
$0.30-1.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.48-0.02%
INTCIntel
$96.69-0.07%
NOKNokia
$10.39-0.04%
NVDANvidia
$219.74-0.02%

Questions About BOIRF

What is the current price of Boiron?

Boiron is trading at $31.50 per share.

What is the 52-week range for Boiron?

Over the past 52 weeks, Boiron has traded between $24.30 and $32.28.

How much debt does Boiron have?

As of the most recent reporting period, Boiron reported total debt of €36.97M.

How much cash does Boiron have on hand?

Boiron reported €93.18M in cash and cash equivalents in its most recent financial results.

What is Boiron’s dividend yield?

Boiron currently has a dividend yield of 4.98%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services